Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132749) titled 'NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd' on Aug. 4.
Study Type: Observational [Patient Registry]
Primary Sponsor: Yeon Hee Park
Condition:
Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd
Patients With HER2-low Advanced Breast Cancer Treated With T-DXd
Recruitment Status: Not recruiting
Date of First Enrollment: August 15, 2025
Target Sample Size: 100
Countries of Recruitment:
Korea, Republic of
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07132749
Published by HT Digital Content Services with permission from Health Daily ...